Action Cel Sci - CVM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,2586

Prix Achat

Prix Vente

Volume échangé

441 070

0,2501 Fourchette du Jour 0,2671

0,18 Plage de 52 semaines 2,39

Cap du marché

19,967M

Clôture Veille

0,2548

Ouverture

0,2599

Dernière Transaction

700

0.2586

Dernière heure de transaction

20:54:59

Volume financier

US$ 114 019

VWAP

0,258505

Volume moyen (3 m)

1 531 854

Actions en circulation

77 211 541

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,73

Bénéfice par action (BPA)

-0,36

Chiffre d'affairess

Bénéfice net

-27,58M

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on th... CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.cel-sci.com

Siège social

Centennial, Colorado, USA

Fondé

Cel Sci Corporation New est coté dans le secteur Biological Pds,ex Diagnstics de la American Stock Exchange avec le ticker CVM. Le dernier cours de clôture d'Cel Sci était de US$0,25. Au cours de la dernière année, les actions de Cel Sci ont été négociées dans une fourchette de prix de US$ 0,18 à US$ 2,39.

Cel Sci compte actuellement 77 211 541 actions en circulation. La capitalisation boursière d'Cel Sci est de US$19,67 million. Cel Sci a un ratio cours/bénéfice (ratio PE) de -0.73.

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire VANCOUVER, BC, April 14...

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire VANCOUVER, BC, April 14...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall...

Form 4 - Statement of changes in beneficial ownership of securities

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Data published in peer-reviewed scientific journal Pathology and Oncology Research Quality of life improvements included reduction in or...

Form PRE 14A - Other preliminary proxy statements

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.0514	-16.5806451613	0.31	0.315	0.2256	1619661	0.24587226	CS
4	-0.0278	-9.70670391061	0.2864	0.32	0.18	1604924	0.24700702	CS
12	-0.1613	-38.4139080734	0.4199	0.6803	0.18	1531854	0.31128711	CS
26	-0.6614	-71.8913043478	0.92	1.09	0.18	1240195	0.4146027	CS
52	-1.2914	-83.3161290323	1.55	2.39	0.18	1027812	0.76271822	CS
156	-3.3114	-92.756302521	3.57	5.4158	0.18	634357	1.57759934	CS
260	-10.3214	-97.5557655955	10.58	40.91	0.18	802275	7.16144892	CS

CVM - Frequently Asked Questions (FAQ)

What is the current Cel Sci share price?

The current share price of Cel Sci is US$ 0,2586

How many Cel Sci shares are in issue?

Cel Sci has 77 211 541 shares in issue

What is the market cap of Cel Sci?

The market capitalisation of Cel Sci is USD 19,67M

What is the 1 year trading range for Cel Sci share price?

Cel Sci has traded in the range of US$ 0,18 to US$ 2,39 during the past year

What is the PE ratio of Cel Sci?

The price to earnings ratio of Cel Sci is -0,73

What is the reporting currency for Cel Sci?

Cel Sci reports financial results in USD

What is the latest annual profit for Cel Sci?

The latest annual profit of Cel Sci is USD -27,58M

What is the registered address of Cel Sci?

The registered address for Cel Sci is 7700 E ARAPAHOE RD, STE 220, CENTENNIAL, COLORADO, 80112 1268

What is the Cel Sci website address?

The website address for Cel Sci is www.cel-sci.com

Which industry sector does Cel Sci operate in?

Cel Sci operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
FLAGGlobal X S&P 500 US Market Leaders Top 50 ETF	US$ 23,92 (199,00%)	701
UVIX2x Long VIX Futures ETF	US$ 64,76 (15,85%)	4,49M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 4,1927 (14,87%)	56,75M
HIBSDirexion Daily S&P 500 High Beta Bear 3x Shares	US$ 27,33 (12,15%)	426,83k
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 4,0001 (11,89%)	45,36M
SCPXScorpius Holdings Inc	US$ 0,068 (-48,48%)	1,31M
CHROChannel Therapeutics Corporation	US$ 1,39 (-24,46%)	710,41k
AXILAXIL Brands Inc	US$ 5,01 (-17,60%)	4,43k
DDCDDC Enterprise Limited	US$ 1,765 (-16,45%)	151,69k
TSLTT Rex 2X Long Tesla Daily Target ETF	US$ 8,9344 (-14,75%)	5,11M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 8,2699 (-10,11%)	202,68M
BTGB2Gold Corp	US$ 3,3627 (1,29%)	79,8M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 5,775 (-1,37%)	76,97M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 8,4849 (9,77%)	59,87M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 4,1927 (14,87%)	56,75M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cel Sci Corporation New (CVM)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Cel Sci Corporation New

CVM Dernières nouvelles

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Form PRE 14A - Other preliminary proxy statements

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cel Sci Corporation New (CVM) Cours

Cel Sci Corporation New (CVM)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Cel Sci Corporation New

CVM Dernières nouvelles

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Form PRE 14A - Other preliminary proxy statements

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités